Mobilizing the Patient's Immune System to Treat Serious Diseases
Cue Biopharma, Inc. (Nasdaq: CUE) is a clinical-stage biopharmaceutical company developing a novel class of engineered biologics to selectively modulate disease-specific T cells for the treatment of autoimmune, inflammatory, and oncological diseases.
LATEST NEWS
CUE Biopharma Announces $30 Million Private Placement and Appoints Shao-Lee Lin, M.D., Ph.D. as CEO, President and Board Director
Identifying The Opportunity
KEY LEVELS
Key Level #1 - $25.69
Key Level #2 - $40.29
Key Level #3 - $57.35
Support: $17.68
Cue Biopharma, Inc.
Selective Immune Modulation Platform
- Cue Biopharma’s platform is designed to selectively activate disease-relevant T cells by mimicking the body’s natural immune signals, targeting immune imbalance without broadly suppressing or overstimulating the immune system.
- Its modular biologics platform allows validated components to be rapidly combined into new therapies, enabling faster and more cost-efficient pipeline expansion.
- The CUE-100 series has shown clinical activity and tolerability across multiple cancer types, providing early human validation for the platform.
- The same core technology is being expanded into autoimmune disease through:
- CUE-400 series → regulatory T cell induction
- CUE-500 series → targeted B cell depletion
- The addition of Ascendant-221, a Phase 2 anti-IgE antibody with a dual mechanism of action, expands Cue’s reach into allergic disease.
Operational Momentum and Scaling
- Cue Biopharma is building a diversified precision immunology pipeline across cancer, autoimmune, and allergic diseases while using partnerships to limit dilution.
- Partnerships with Boehringer Ingelheim and ImmunoScape validate its platform and expand the pipeline into new therapeutic areas.
- Ascendant-221 expands exposure to the allergy market, with Phase 2 data expected in 2H 2026.
Positioning for Long-Term Growth
- Cue Biopharma is building a diversified precision immunology business focused on cancer, autoimmune, and allergic diseases while using partnerships to reduce reliance on dilution.
- Collaborations with Boehringer Ingelheim and ImmunoScape validate its platform technology and expand its pipeline into new therapeutic areas.
- The addition of Ascendant-221 strengthens exposure to the growing allergy market, with Phase 2 data expected in the second half of 2026.
Financials
Cue Biopharma has demonstrated measurable improvement in its financial profile over the past year, driven by milestone payments and collaboration revenue from its strategic partnerships.
Key Financial Highlights:
• Cash and Equivalents: $16.4M (as of March 31, 2026)
• Collaboration Revenue (Q1 2026): $5.7M (up from $0.4M in Q1 2025)
• Q1 2026 Net Loss: $(5.2M) (vs. $(12.3M) in Q1 2025)
• R&D Expenditures: $6.9M (Q1 2026)
• Private Placement (April/May 2026): $27.6M net proceeds (closed May 4, 2026)
• Boehringer Milestone Earned: $7.5M (April 2026; first compound optimization)
Introducing the Leadership Team of Cue Biopharma, Inc.(Nasdaq: CUE)
Shao-Lee Lin
Chief Executive Officer, President and Board Director since April 30, 2026
Dr. Shao-Lee Lin brings more than 25 years of biopharmaceutical leadership experience to Cue Biopharma. Prior to joining Cue, she was the founder and Chief Executive Officer of ACELYRIN, a Nasdaq-listed biotechnology company that she took public within three years of incorporation at a valuation exceeding $2 billion, having secured over $1 billion in capital from leading investors during her tenure. Earlier in her career, Dr. Lin served as Chief Scientific Officer and Head of Research and Development at Horizon Therapeutics and held senior leadership roles at AbbVie, Gilead Sciences, and Amgen. She has contributed to the development of multiple approved medicines including TEPEZZA, SKYRIZI, and RINVOQ. Dr. Lin has served on several public company boards including Principia Biopharma, Third Harmonic Bio, and Surrozen. She holds an M.D. and Ph.D. from the Johns Hopkins University School of Medicine and graduated magna cum laude with a bachelor's degree in chemical engineering and biochemistry from Rice University.
Daniel Baker
Interim Chief Development Officer
Dr. Baker is a physician with over two decades of pharmaceutical experience, having spent nearly 20 years at Johnson & Johnson (Janssen/Centocor) as VP of Immunology R&D. There, he led clinical development for major drugs like Remicade, Simponi, and Stelara, overseeing numerous trials that resulted in more than 15 regulatory approvals across the US, Europe, and Japan.
He later shifted into a strategic leadership role as Disease Area Stronghold Leader, focusing on rheumatology portfolio development. After retiring from Janssen in 2019, he founded and led Kira Therapeutics, then served on Galapagos Therapeutics' board from 2022 to 2024. He earned his medical degree from the University of Pennsylvania and completed training in rheumatology and immunology through residencies and fellowships at Penn, Hershey Medical Center, and Massachusetts General Hospital.
Colin Sandercock
Senior Vice President and General Counsel
Colin Sandercock serves as Senior Vice President and General Counsel of Cue Biopharma, and also serves as Secretary of the company. He supports the company's legal, compliance, and corporate governance functions, and has played a central role in the company's partnership agreements and corporate actions, including the 2026 Annual Meeting of Stockholders.
We get our information from SEC filings and verified public sources.
Stay Ahead. Stay Informed. Stay Profitable.
Subscribe to See What They're Watching
Sources
https://www.cuebiopharma.com/https://www.sec.gov/ (CUE SEC Filings)https://www.globenewswire.com/ (Press Releases)https://www.nasdaq.com/ (FY2025 Results)https://www.tradingview.com/symbols/NASDAQ-CUE/
Disclaimer
Disclaimer
Stock Research Today is a project of Virtus Media Group LLC and intended solely for entertainment and informational purposes. This website / media webpage is owned, operated and edited by Virtus Media LLC. Any wording found on this website / media webpage or disclaimer referencing “I” or “we” or “our” or “Virtus Media” refers to Virtus Media LLC. This website / media webpage is a paid advertisement, not a recommendation nor an offer to buy or sell securities. By reading our website / media webpage you agree to the terms of this disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investment or brokerage advice or anything of an advisory or consultancy nature and therefore are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis for making investment decisions and is for entertainment and educational purposes only. At most, this communication should serve as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. Consult your financial, investment and tax advisors to determine what financial and tax strategies may be right for you. Investor protection and other important information is available at https://www.sec.gov/.
By using our service, you agree not to hold our site, its editors, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within or referred to from our website / media webpage. We do not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Never invest purely based on our alerts. Gains mentioned in our website / media webpage may be based on end-of-day or intraday data.
This publication and its owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares we will list the information relevant to the stock and number of shares here. That information is only valid at the time it is published, and we do not undertake to update it.
Virtus Media’s business model is to receive financial compensation to promote public companies and to conduct investor relations advertising, marketing and publicly disseminate information, not limited to our websites, email, sms, push notifications, influencers, social media postings, ticker tags, press releases, online interviews, podcasts, videos, audio ads, banner ads, native ads, and responsive ads. This compensation is a major conflict of interest in our ability to be unbiased regarding the subject of our reports and communications. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the parties who hired us, or of the profiled companies. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts.
The third parties paying for our services, the profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to impact share prices, possibly significantly. Frequently companies profiled in our alerts experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases.
We do not guarantee the timeliness, accuracy, or completeness of the information on our website / media webpage. The information in our website / media webpage is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, Virtus Media often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. Our emails may contain forward-looking statements, which are not guaranteed to materialize due to a variety of factors.
Pursuant to an agreement between Preservation Services LLC and Virtus Media Group LLC, Virtus Media has been hired to publicly disseminate information about ticker $CUE via digital communications beginning May 14th, 2026 ending August 15th, 2026. Virtus will be paid $270,000 from Preservation Services LLC
